Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT201105236568N1
IRCT201105236568N1CompletedPhase 2

Effects of topical interferon Gamma 1b in the treatment of uveitic cystoid macular edema

Tabriz University of Medical Sciences0 sites10 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 60 years (—)
Sex
All

Inclusion Criteria

  • •(to have medial, posterior or pan-uveitis at least 3 months before the participation in the study together with macular cystoid edema secondary to uveitis in at least one eye; to have visual acuity equal or greater than 20/200; to be 18 to 60 year-old; to have a central macular thickness greater than 250 micrometers)
  • •Exclusion criteria: (pregnancy or breast feeding; occurrence of intolerable adverse effects; to have a history of herpetic kerititis and multiple sclerosis; to have an active infection which needs an urgent treatment; history of chronic or recurrent infections)

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Completed
Phase 3
Clinical trial for evaluation of the effect of topical interferon a2b as a complementary treatment of macular edema of patients with diabetic retinopathy compared with placebodiabetic retinopathy.Diabetic retinopathy
IRCT2016081529370N1Vice chancellor for research of Shiraz University of Medical Sciences50
Completed
Phase 2
The efficacy of topical interferon alpha-2b in pterygiumpterygium.Pterygium of eyeH11.0
IRCT20190806044463N1Bagheiat-allah University of Medical Sciences18
Active, not recruiting
Not Applicable
A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapysteroid-refractory bronchiolitis obliteransMedDRA version: 13.1Level: PTClassification code 10029888Term: Obliterative bronchiolitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-022467-36-DEFreistaat Bayern
Recruiting
Phase 3
Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19
IRCT20120703010178N25Shahid Beheshti University of Medical Sciences100
Recruiting
Phase 3
ReciGen for treatment of Covid-19Covid 19.COVID-19, virus identifiedU07.1
IRCT20150914024017N1Tehran University of Medical Sciences40